Dare Bioscience, Inc. quarterly report, Q3 FY2023

Daré Bioscience, Inc. — Q3 2023 Form 10-Q

Reporting period: Quarter and nine months ended September 30, 2023. Daré is a women’s-health biopharmaceutical company whose operations principally involve research and development. XACIATO, its FDA-approved bacterial-vaginosis treatment, is commercialized by Organon under an exclusive license; the first U.S. commercial shipment occurred in October 2023.

Financial results and position

MetricQ3 2023Q3 2022Nine months 2023Nine months 2022
Revenue$1.0 million$0$1.0 million$10.0 million
Operating expenses$9.4 million$7.1 million$26.8 million$25.2 million
Operating loss$8.4 million$7.1 million$25.8 million$15.2 million
Net loss$8.3 million$7.0 million$25.1 million$15.0 million
Basic and diluted loss per share$0.09$0.08$0.29$0.18
Operating cash usedNot stated for quarterNot stated for quarter$30.7 million$12.2 million

Q3 revenue was the $1.0 million payment under the amended Organon license. Nine-month 2022 revenue included the $10.0 million XACIATO upfront license payment. No product-sales revenue or royalties were reported through September 30. A conventional revenue-based margin is not informative given the small, license-driven revenue base and continuing development costs.

At September 30, cash and cash equivalents were $13.9 million, total assets $25.1 million, current liabilities $26.3 million, total liabilities $27.3 million, and stockholders’ deficit $2.3 million. Working capital deficit was approximately $3.9 million. Deferred grant funding liabilities were $15.7 million; most cash was grant-funded and restricted to eligible DARE-LARC1 and DARE-LBT costs, with approximately 10% available for supporting overhead. The filing reports approximately $0.5 million remaining on insurance-premium financing and $0.2 million of current lease liabilities; it does not report material conventional long-term borrowings.

For the nine months, investing cash use was $0.02 million and financing cash provided was $10.3 million, including the September equity-and-warrant offering, ATM sales, warrant exercises, and insurance financing. Cash, cash equivalents and restricted cash declined by $20.4 million to $14.2 million.

Changes, outlook and risks

  • Year-to-date net loss increased 67% year over year as revenue fell by $9.0 million, while operating expenses rose 6%. Q3 R&D expense increased 50% year over year, primarily due to Sildenafil Cream Phase 2b work and Ovaprene activities.
  • Management stated that available cash was insufficient for working-capital needs and other liquidity requirements for at least 12 months from the financial-statement issuance date, and that additional capital was needed to fund operations into Q1 2024. The filing identifies substantial doubt about the company’s ability to continue as a going concern. Financing availability, timing and terms are uncertain.
  • Until additional capital is secured, management planned to prioritize Ovaprene and Sildenafil Cream, while grant funding supports DARE-LARC1 and DARE-LBT. DARE-HRT1 Phase 3 and DARE-VVA1 Phase 2 were not planned to proceed until additional capital was obtained. No quantified revenue or earnings guidance was provided.
  • Management anticipated starting Ovaprene’s pivotal Phase 3 enrollment before year-end 2023, targeting about 250 women to complete 13 menstrual cycles. Daré had paid $5.0 million of its $5.5 million CRADA commitment; further study costs could arise. Sildenafil Cream Phase 3 design depended on FDA discussions. These are forward-looking plans, not completed milestones.
  • In October 2023, Daré became entitled to a $1.8 million Organon first-commercial-sale milestone, expected to be recognized in Q4, and incurred a $0.5 million payment obligation to a third-party licensor. These were subsequent events, not Q3 revenue or expense.
  • The September offering raised approximately $6.8 million net from 10.0 million shares and warrants for another 10.0 million shares at $0.77 exercise price. Warrants become exercisable six months after issuance. The company also reported a Nasdaq minimum-bid-price deficiency, with a January 16, 2024 compliance date; its negative stockholders’ equity could affect eligibility for an additional compliance period.
  • Other notable risks include dependence on grant funding and collaborators, clinical and regulatory uncertainty, commercialization and supply execution, potential dilution or unfavorable financing, and a reported $0.2 million net business-email-compromise fraud loss during the nine-month period. Management reported effective disclosure controls and no material pending legal proceedings.

Important facts for investors to verify

  • Whether Daré secured sufficient additional capital, on what terms, and whether it materially changed spending plans or the going-concern assessment.
  • Actual unrestricted cash and near-term cash burn, given the substantial grant restrictions and working-capital deficit.
  • Organon’s commercial launch progress, XACIATO sales and royalties, and timing of the $1.8 million milestone payment.
  • Ovaprene study start, enrollment, budget and any additional funding needs; FDA feedback and the next development steps for Sildenafil Cream.
  • Nasdaq bid-price compliance and continued-listing eligibility, plus potential dilution from warrants, options and further equity issuance.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.